<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="17154">Nicotinamide</z:chebi> <z:chebi fb="1" ids="16708">adenine</z:chebi> dinuleotide (<z:chebi fb="0" ids="15846">NAD(+)</z:chebi>) plays critical roles in multiple biological functions </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies have indicated that <z:chebi fb="0" ids="15846">NAD(+)</z:chebi> treatment decreases <z:mp ids='MP_0003674'>oxidative stress</z:mp>-induced <z:hpo ids='HP_0011420'>death</z:hpo> of primary neurons and astrocytes </plain></SENT>
<SENT sid="2" pm="."><plain>Intranasal administration of <z:chebi fb="0" ids="15846">NAD(+)</z:chebi> also reduces brain damage in a rat model of transient focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>However, the mechanisms underlying this protective effect remain unknown </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we used a mouse model of <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> to test our hypothesis that <z:chebi fb="0" ids="15846">NAD(+)</z:chebi> decreases ischemic brain damage partially by preventing autophagy </plain></SENT>
<SENT sid="5" pm="."><plain>Adult male mice were subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (tMCAO) for 90min, and <z:chebi fb="0" ids="15846">NAD(+)</z:chebi> was administered intraperitoneally (i.p.) immediately after reperfusion started </plain></SENT>
<SENT sid="6" pm="."><plain>We found that administration with 50mg/kg <z:chebi fb="0" ids="15846">NAD(+)</z:chebi> led to significant decreases in <z:mpath ids='MPATH_124'>infarct</z:mpath> size, <z:hpo ids='HP_0000969'>edema</z:hpo> formation, and neurological deficits at 48h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="15846">NAD(+)</z:chebi> administration also significantly decreased <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>-induced autophagy in the cortex and hippocampus </plain></SENT>
<SENT sid="8" pm="."><plain>We further found that prevention of autophagy by <z:chebi fb="0" ids="38635">3-methyladenine</z:chebi> (3-MA), a selective autophagy inhibitor, significantly reduced ischemic brain damage, suggesting an important role of autophagy in the ischemic brain injury in our animal model </plain></SENT>
<SENT sid="9" pm="."><plain>Collectively, our findings have suggested that <z:chebi fb="0" ids="15846">NAD(+)</z:chebi> administration decreases ischemic brain damage at least partially by blocking autophagy </plain></SENT>
<SENT sid="10" pm="."><plain>This is the first suggested mechanism regarding the protective effects of <z:chebi fb="0" ids="15846">NAD(+)</z:chebi> in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, which further highlights the promise of <z:chebi fb="0" ids="15846">NAD(+)</z:chebi> for treating <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
</text></document>